RecruitingRecruiting
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
NCT07223021 · Memorial Sloan Kettering Cancer Center
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Improving EveNt Free Survival by Optimizing FLUdarabine Exposure During LymphodepletioN for CAR T CEll Therapy: a Randomized, Multi-center Study of Children and Young Adults With B-cell Acute Lymphoblastic Leukemia (INFLUENCE)
About this study
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will receive tisagenlecleucel CAR T-cell therapy. The researchers will compare PK-targeted fludarabine dosing with standard fludarabine dosing to see which treatment approach is more effective. The researchers will also look at whether PK-targeted fludarabine dosing is feasible (practical), the side effects of the study treatment, and how the study treatment affects people's quality of life. The researchers will measure quality of life by having participants complete questionnaires.
Eligibility criteria
Inclusion Criteria:
* Patients with B-ALL and eligible to receive commercial tisagenlecleucel.
* Patient's weight \> 9 kg at time of lymphodepleting chemotherapy
* Adequate organ function at time of LD is required and is defined:
* Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia
* Hepatic: AST and ALT \< 5x the upper limit of normal for age, unless thought to be leukemic disease-related
* Renal: Calculated glomerular filtration rate (GFR) ≥ 70 ml/min/1.73m\^2. (based on Schwartz formula GFR (mL/min/1.73 m²) = (36.2 × Height in cm) / Creatinine in mg/dL
* Cardiac: LVEF ≥ 50% by multi-gated acquisition scan (MUGA), resting echocardiogram, or cardiac magnetic resonance imaging (MRI) within 6 weeks of screening
* Pulmonary: Oxygen saturation as recorded by pulse oximetry of ≥ 90% on room air
* Adequate performance status:
* Age ≥ 16 years: ECOG ≤ 1 or Karnofsky \> 60% at treatment
* Age \< 16 years: Lansky ≥ 60% at treatment
* Willing to participate as research subject and provide written informed consent from parents/legal representative, patient, and age-appropriate assent as appropriate before any study specific screening procedures are conducted, according to local, regional or national law and legislation.
Exclusion Criteria:
* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to the study drugs, or drugs chemically related to study treatment or excipients that contraindicate their participation, including fludarabine, cyclophosphamide and tisagenlecleucel.
* Patients with tisagenlecleucel that is deemed out of specification (OOS) will be excluded from this protocol
* Clinically significant active and uncontrolled infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA etc.)
* Patient/parent/guardian unable to give informed consent or unable to comply with the treatment protocol.
* Pregnant or lactating women
Study design
Enrollment target: 130 participants
Allocation: randomized
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2025-10-20
Estimated completion: 2028-10
Last updated: 2026-06-04
Interventions
Drug: FludarabineDrug: CyclophosphamideDrug: FludarabineBiological: CAR-T
Primary outcomes
- • compare the event free survival (EFS ) (28 days)
Sponsor
Memorial Sloan Kettering Cancer Center · other
With: Princess Maxima Center for Pediatric Oncology
Contacts & investigators
ContactKevin Curran, MD · contact · currank@mskcc.org · 1-833-MSK-KIDS
ContactJaap Jan Boelens, MD, PhD · contact · 1-833-MSK-KIDS
InvestigatorKevin Curran, MD · principal_investigator, Memorial Sloan Kettering Cancer Center
All locations (3)
Memorial Sloan Kettering Cancer CenterRecruiting
New York, New York, United States
Cincinnati Children's Hospital Medical Center (Data Collection Only)Recruiting
Cincinnati, Ohio, United States
Children's Hospital of Philadelphia (Data Collection Only)Recruiting
Philadelphia, Pennsylvania, United States